摘要:
The present invention relates to the Lactobacillus paracasei strain deposited at the CNCM under reference number CNCM I-5369 The present invention also relates to a mixture of the peptides having the following sequences: (SEQ ID NO 1), (SEQ ID NO 2), (SEQ ID NO 3), (SEQ ID NO 4) and (SEQ ID NO 5) and to one of the above-mentioned peptides in combination with at least one component chosen among: - essential oils and particularly among essential oil of mint, essential oil of thyme, essential oil of pine tree, menthol, thymol, pinene, - vitamin C, formic acid, propionic acid, citric acid, sorbic acid and lactic acid and/or - a nanoparticle which may be loaded with said active ingredients.
摘要:
본 발명은 유산균 유래 단백질 및 이의 제조방법에 관한 것이다. 본 발명의 유산균 유래 단백질은 대장암에 대한 치료 효과가 우수한 유산균(락토바실러스 램노서스)으로부터 분리한 정제 단백질로서 대장질환에 대하여 현저한 효과를 입증하였으므로, 천연 단백질 대장질환 치료제로서 의학 분야에서 크게 활용될 것으로 기대된다.
摘要:
Provided herein are microorganisms engineered with heme-responsive transcription factors and genetic circuits. Also provided are methods for using engineered microorganisms to sense bleeding events and treat bleeding in vivo.
摘要:
The present invention relates to isolated polypeptides having cellulytic enhancing activity. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
摘要:
The present invention relates to compositions, including live organisms, nucleic acid and amino acid sequences, constructs and cells comprising these, which are used to competitively exclude pathogenic organisms from the alimentary canals of vertebrates to achieve prophylaxis or therapeutic effects.
摘要:
The present invention provides therapeutic and prophylactic compositions for use in treating and preventing disorders involved epithelial cell apoptosis, such as gastrointestinal disorders (e.g., inflammatory bowel disease, Crohn's disease or ulcerative colitis) in a subject, such as a human patient.
摘要:
The present invention relates to novel bacteriocin-producing lactic acid bacteria strains Lactococcus lactis subsp. lactis MM19 accession number NML-080508-01and Pediococcus acidilactici MM33 accession number NML-080508-02 isolated from the human gut. The strains L. lactis subsp. l actis MM19 and P. acidilactici MM33 and the bacteriocins produced by these strains are useful for inhibiting microbial growth in food products, and for inhibiting microbial infection or colonization of a mammal.
摘要:
The present invention relates to Gram positive bacteria with increased stress tolerance, reduced virulence, and/or reduced mobility, as a result of an altered CtsR protein. The alteration of the CtsR protein in particular concerns an alteration of the conserved glycine-rich region in the CtsR protein. The invention further relates to nucleic acid encoding the altered CtsR proteins. The altered Gram positive bacteria may be used in fermentation processes and may be used as delivery vehicles for site specific delivery of therapeutic proteins such as vaccines.